Home

About ICSI
   Program description
   Members
   Board of directors
   Staff directory
   Annual report
   Map & directions
   Bibliography

Colloquium on
Clinical Quality Improvement
   Information
   Agenda
   Registration

Events (open to public)

Publications

Clinical improvement
   Concepts
   Methods
   Studies

Health care guidelines

Technology assessment reports

Contact us
Advertising & privacy policies

We subscribe to the HONcode principles. Verify here

As you review the ICSI health care guideline on treatment of lipid disorder in adults, please note that cerivastatin (Baycol®) is no longer available. Language in the guideline referring to cerivastatin has been crossed out. The ICSI Lipid Treatment Guideline Work Group will review the full guideline in fall 2001. A revised guideline will be available in early 2002.

On August 8, 2001, Bayer Pharmaceutical Division voluntarily withdrew Baycol® from the US market because of reports of sometimes fatal rhabdomyolysis, a severe muscle adverse reaction, from this cholesterol-lowering (lipid-lowering) product. In a letter to the FDA, Bayer stated that patients who are currently taking Baycol® should have their Baycol® discontinued and be switched to an alternative therapy.

To read the latest MedWatch 2001 safety summary for Baycol®, including Bayer's "Dear Health Professional" letter and FDA's Talk Paper and Q&A web pages, go to http://www.fda.gov/medwatch/safety/2001/safety01.htm#bayco2.

Access ICSI guideline on treatment of lipid disorder in adults

last updated: 2/28/2002